Aeras Global TB Vaccine Foundation, Crucell N.V. and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa

LEIDEN, NETHERLANDS--(Marketwire - April 09, 2008) - Atlanta, Georgia, USA / Leiden, The Netherlands, 9 April 2008 - Dutch biotechnology company Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative (SATVI) present a progress update and immunology data from a Phase I Ad35 tuberculosis vaccine study at the biennial "Tuberculosis Vaccines for the World" conference (Atlanta, Georgia, April 9 to 11) today. The study, conducted in Worchester, South Africa and launched in May 2007, is the second phase I study in a current series of three and has revealed promising results.